Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24247724 | 0.83 | PDE10A (0.55) | PDE10ATLR7ALDH1A1KDM4ERAB9A | |
| SCHEMBL2550713 | 0.82 | PDE10A (0.57) | PDE10ATLR7ALDH1A1KDM4ERAB9A | |
| SCHEMBL2100275 | 0.81 | HTR2B (0.59) | PDE10ATLR7ALDH1A1KDM4ERAB9A | |
| SCHEMBL2549198 | 0.80 | MAOA (0.59) | PDE10ATLR7ALDH1A1KDM4ERAB9A | |
| SCHEMBL20646870 | 0.80 | PDE10A (0.55) | PDE10ATLR7ALDH1A1KDM4ERAB9A | |
| SCHEMBL12158528 | 0.79 | HDAC1 (0.60) | TLR7ALDH1A1KDM4ERAB9AMAPT | |
| SCHEMBL2551392 | 0.77 | TLR7 (0.56) | PDE10ATLR7ALDH1A1 | |
| SCHEMBL31341080 | 0.77 | TLR7 (0.56) | PDE10ATLR7ALDH1A1 | |
| SCHEMBL2436892 | 0.77 | LMNA (0.62) | PDE10ATLR7ALDH1A1RAB9AMAPT | |
| SCHEMBL31341038 | 0.77 | LMNA (0.62) | PDE10ATLR7ALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | PDE10A 195/4885TLR7 1792/4885ALDH1A1 895/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | PDE10A 186/4885TLR7 1860/4885ALDH1A1 892/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | PDE10A 195/4885TLR7 1792/4885ALDH1A1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.